Dr. Sita Kugel receives $100K grant to study pancreatic neuroendocrine tumors

Hutch News

Dr. Sita Kugel receives $100K grant to study pancreatic neuroendocrine tumors

She will use preclinical models to study the role of DNA packaging in cancer development and metastasis

March 29, 2018
Dr. Sita Kugel

Dr. Sita Kugel

Fred Hutch file photo

Dr. Sita Kugel of the Human Biology Division at Fred Hutchinson Cancer Research Center has received a one-year, $100,000 grant from the Neuroendocrine Tumor Research Foundation to study how a gene involved in modifying DNA may play a role in suppressing the development of pancreatic neuroendocrine tumors.

Tumors in the pancreas arise from two types of cells: exocrine cells, which make digestive enzymes, and endocrine cells, which make insulin. About 10 percent of pancreatic cancers begin as endocrine cells. Unfortunately, many patients with pancreatic neuroendocrine tumors, or PNETs,  are only diagnosed after the disease has begun to spread to other sites in the body. Patients need better treatments, particularly ones that tackle metastasis.

But there are few model systems of PNETs in which scientists can gain a deeper understanding of how PNETs develop, what drives the more metastatic version of the disease, and what molecules could serve as therapeutic targets.

“This has been a real bottleneck for research,” Kugel said.

But she has developed a preclinical model system that appears to align with many of the features of human PNETs. She works on a molecule called sirtuin 6, which helps keep DNA tightly packed and genes turned off. Kugel found that loss of SIRT6 in the pancreas, in conjunction with the loss of cell cycle checkpoint gene p53, triggered spontaneous, highly metastatic tumors of the organ’s endocrine cells.

Kugel has created an even more targeted preclinical model to study how SIRT6 may work to suppress metastasis of PNETs. She will also use the grant to look more closely at SIRT6 loss in human PNETs and compare her models to clinical reality. Kugel’s work in pancreatic ductal carcinomas has suggested that tumors that are low in SIRT6 are more sensitive to certain targeted therapies. Her studies of PNETs with low SIRT6 levels may reveal if these tumors have the same susceptibility.

“We want to understand how SIRT6 is suppressing both PNETs and PNET metastasis,” Kugel said. The goal is to understand the role of SIRT6 in PNET pathogenesis.

Read more about Fred Hutch achievements and accolades.

Sabrina Richards, a staff writer at Fred Hutchinson Cancer Research Center, has written about scientific research and the environment for The Scientist and OnEarth Magazine. She has a Ph.D. in immunology from the University of Washington, an M.A. in journalism and an advanced certificate from the Science, Health and Environmental Reporting Program at New York University. Reach her at srichar2@fredhutch.org.

Are you interested in reprinting or republishing this story? Be our guest! We want to help connect people with the information they need. We just ask that you link back to the original article, preserve the author’s byline and refrain from making edits that alter the original context. Questions? Email us at communications@fredhutch.org


(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.